Top 28 Immunology startups in USA
May 04, 2026
|
Like
15
1
Funding: $700M
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
2
Funding: $634M
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
3
Funding: $569M
Alumis is a precision medicines company that is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.
Alumis is a precision medicines company that is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.
4
Funding: $566.8M
Atara Biotherapeutics develops allogeneic T-cell immunotherapies for the treatment of cancer, autoimmune diseases and viral diseases. The company's platform is based on allogeneic, or donor T cells that are enriched during the manufacturing process for specific receptors targeting the Epstein-Barr virus (EBV). These EBV T cells are modified with CAR to generate allogeneic CAR T-cell therapies for a broad range of antigen targets. Our molecular suite of clinically validated technologies, including the 1XX costimulatory domain, engineered to optimize physiological signaling leading to reduced exhaustion while maintaining a memory phenotype, offers a differentiated approach to addressing the significant unmet need for next-generation CAR T cells. Atara is conducting clinical trials of its candidates for the treatment of lupus nephritis and B-cell malignancies.
Atara Biotherapeutics develops allogeneic T-cell immunotherapies for the treatment of cancer, autoimmune diseases and viral diseases. The company's platform is based on allogeneic, or donor T cells that are enriched during the manufacturing process for specific receptors targeting the Epstein-Barr virus (EBV). These EBV T cells are modified with CAR to generate allogeneic CAR T-cell therapies for a broad range of antigen targets. Our molecular suite of clinically validated technologies, including the 1XX costimulatory domain, engineered to optimize physiological signaling leading to reduced exhaustion while maintaining a memory phenotype, offers a differentiated approach to addressing the significant unmet need for next-generation CAR T cells. Atara is conducting clinical trials of its candidates for the treatment of lupus nephritis and B-cell malignancies.
5
Funding: $414.8M
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
6
Funding: $400M
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
7
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
8
Funding: $356M
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
9
Funding: $328M
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
10
Funding: $310M
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
11
Funding: $300M
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
12
Funding: $247M
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
13
Funding: $208M
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune.
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune.
14
Funding: $207M
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
15
Funding: $199M
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
16
Funding: $183M
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
17
Funding: $177M
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases.
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases.
18
Funding: $176M
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
19
Funding: $165M
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
20
Funding: $133.8M
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
21
Funding: $121M
Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.
Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.
22
Funding: $120M
Ouroboros Medicines is a biotechnology company specializes in immunology.
Ouroboros Medicines is a biotechnology company specializes in immunology.
24
Funding: $89.6M
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
25
Funding: $50M
Metaphore Biotechnologies is a firm that uses biomimicry and machine learning to unlock the revolutionary therapeutic. The company aims the platform at developing treatments for autoimmune, metabolic and oncology indications.
Metaphore Biotechnologies is a firm that uses biomimicry and machine learning to unlock the revolutionary therapeutic. The company aims the platform at developing treatments for autoimmune, metabolic and oncology indications.
26
Funding: $50M
Cimeio Therapeutics is applied gene editing, cellular and immunotherapy company, developing shielded-cell and immunotherapy pairs to transform treatment for rare genetic diseases, hematologic malignancies and autoimmune disorders.
Cimeio Therapeutics is applied gene editing, cellular and immunotherapy company, developing shielded-cell and immunotherapy pairs to transform treatment for rare genetic diseases, hematologic malignancies and autoimmune disorders.
27
Funding: $26.2M
WellTheory is a virtual care platform providing autoimmune and inflammatory conditions care services.
WellTheory is a virtual care platform providing autoimmune and inflammatory conditions care services.
28
Funding: $19.1M
MARAbio is a biotech firm that works to detect and prevent severe forms of Autism.
MARAbio is a biotech firm that works to detect and prevent severe forms of Autism.
★
See also:
